Previous
Previous

2015.06.11. Efficacy of INV-17 ROR gamma inhibitor in a mouse Lupus model highlighted at the EULAR 2015 meeting in Rome, Italy

Next
Next

2014.07.25. Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its oral NCE INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases